Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Drops By 27.3%

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totaling 4,183,761 shares, a decrease of 27.3% from the December 31st total of 5,752,164 shares. Approximately 7.7% of the company’s stock are sold short. Based on an average daily volume of 723,298 shares, the days-to-cover ratio is presently 5.8 days. Based on an average daily volume of 723,298 shares, the days-to-cover ratio is presently 5.8 days. Approximately 7.7% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Wedbush set a $13.00 price objective on shares of Astria Therapeutics and gave the company a “neutral” rating in a research note on Wednesday, October 15th. HC Wainwright cut Astria Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 16th. Cantor Fitzgerald downgraded Astria Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Wednesday, November 12th. Citizens Jmp lowered Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 15th. Finally, Jefferies Financial Group downgraded Astria Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the company from $30.00 to $13.00 in a report on Tuesday, October 14th. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Astria Therapeutics has an average rating of “Hold” and an average price target of $24.50.

Institutional Trading of Astria Therapeutics

Several large investors have recently modified their holdings of the business. Russell Investments Group Ltd. raised its position in shares of Astria Therapeutics by 10,311.8% in the third quarter. Russell Investments Group Ltd. now owns 3,540 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 3,506 shares during the last quarter. Farther Finance Advisors LLC grew its stake in Astria Therapeutics by 185.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,557 shares during the period. Brevan Howard Capital Management LP purchased a new stake in Astria Therapeutics in the 3rd quarter worth approximately $98,000. AXQ Capital LP acquired a new position in Astria Therapeutics in the 3rd quarter valued at $115,000. Finally, Bailard Inc. purchased a new position in shares of Astria Therapeutics during the 2nd quarter worth $142,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Trading Up 0.6%

Shares of ATXS opened at $12.58 on Friday. The stock’s 50 day moving average is $12.77 and its two-hundred day moving average is $10.09. Astria Therapeutics has a twelve month low of $3.56 and a twelve month high of $13.29. The firm has a market capitalization of $718.13 million, a PE ratio of -5.88 and a beta of 0.01.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.14). The business had revenue of $0.71 million for the quarter, compared to the consensus estimate of $10.67 million. On average, sell-side analysts predict that Astria Therapeutics will post -1.65 EPS for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.